Abstract Library

#4625 Efficacy and safety of capecitabine-temozolomide (CAPTEM) regimen in patients with neuroendocrine neoplasms – A systematic review and experience from NETwerk, a Belgian ENETS Center of Excellence

Introduction: Current treatment guidelines remain inconclusive due to scarcity of data regarding the optimal systemic treatment for metastatic gastroenteropancreatic (GEP) neuroendocrine tumours (NET) grade 3 and aggressive GEP-NET grade 2. Similarly, for metastatic pulmonary typical (TC) and atypical carcinoids (AC), the indication for chemotherapy is unclear. Recent evidence highlights a promising role for CAPTEM, combining temozolomide (TEM) with capecitabine (CAP), showing encouraging antitumoural activity and safety profiles for these indications.

Conference:

Presenting Author: Chhajlani S

Authors: Chhajlani S, Lambrechts C, Islam O, de Weerdt C, Verbruggen L,

Keywords: capecitabine, temozolomide, CAPTEM, GEP-NET, pulmonary NEN, safety, efficacy, systematic review,

#4532 Gender differences in patients with medullary thyroid cancer (MTC): A single-centre experience

Introduction: Medullary thyroid cancer (MTC) accounts for 3-5% of thyroid tumours. It can be sporadic or associated with genetic syndrome. The role of gender in the MTC isn’t clarified.

Conference:

Presenting Author:

Authors: Cannavale G, Minotta R, Liccardi A, Benevento E, Di Iasi G,

Keywords: MTC, gender difference, gender medicine,

#4503 Duodenopancreatic neuroendocrine tumour in MEN1: Gender difference and survival rates

Introduction: Multiple endocrine neoplasia type 1 (MEN1) is the most common inherited syndrome associated with NET development and metastatic duodenal-pancreatic (DP) NET is the main cause of death.

Conference:

Presenting Author: Liccardi A

Authors: Liccardi A, Roberto M, Cannavale G, Benevento E, Di Iasi G,

Keywords: Multiple endocrine neoplasia type 1, neuroendocrine tumour, gender difference, survival,

#4455 Multicentric ENETS morphological and molecular appraisal of high-grade gastroenteropancreatic neuroendocrine neoplasms (HG-GEP-NEN): Distinguishing NET G3 from NEC

Introduction: HG-GEP-NEN are classified into neuroendocrine tumours grade 3 (NET G3) and neuroendocrine carcinomas (NEC). This distinction is crucial as it affects patient prognosis and treatments but can be challenging.

Conference:

Presenting Author: Tihy M

Authors: Tihy M, Solstad O, Oudijk L, Bräutigam K, Bani M,

Keywords: HG-GEP-NEN, neuroendocrine neoplasm, NEC, NET G3, Classification, Review, criteria, diagnosis, pathology,

#4448 Statins and somatostatin analogues in gastroenteropancreatic neuroendocrine tumours (GEP-NET): Impact on overall survival

Introduction: Gastroenteropancreatic neuroendocrine tumours (GEP-NET) are rare neoplasia with unclear risk factor influencing their development and survival. Statins appear to enhance antiproliferative effect of some chemotherapies in other cancers, but their effect in GEP-NET treated with somatostatin analogues (SSA) are largely unknown.

Conference:

Presenting Author: Benevento E

Authors: Benevento E, Liccardi A, Minotta R, Cannavale G, Di Iasi G,

Keywords: statins, neuroendocrine tumour, gastroenteropancreatic, overall survival, somatostatin analogue,